BioBlast Pharma Reports Second Quarter Financial Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BioBlast Pharma Reports Second Quarter Financial Results

TEL AVIV, Israel, Aug. 29, 2014 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq: ORPN ), a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases, today announced financial results for the second quarter ended June 30, 2014.

Second Quarter Ended June 30, 2014 Financial Results:

  • Total operating expenses were $1.11 million, compared with $0.64 million in the first quarter of 2014 and $0.13 million in the second quarter of 2013.
  • Research and development (R&D) expenses were $0.72 million, compared with $0.44 million in the first quarter of 2014 and $0.05 million in the second quarter of 2013. R&D expenses consist primarily of costs associated with the preclinical and clinical development of product candidates.
  • General and administrative (G&A) expenses were $0.39 million, compared with $0.20 million in the first quarter of 2014 and $0.09 million in the second quarter of 2013.
  • Cash, cash equivalents and short-term deposits totaled $4.24 million at June 30, 2014 compared with $0.27 million at December 31, 2013 and does not reflect proceeds from the August 5 initial public offering, as outlined below.

Recent Operational Highlights:

  • On August 5, the Company completed a successful initial public offering of 3.2M ordinary shares at $11.00 per share generating net proceeds of approximately $31.6 million, after deducting underwriting discounts and commissions and estimated offering expenses.
  • Received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) on a composition-of-matter patent for its novel fusion protein for Friedrich's Ataxia (referred to as BB-FA) that is built on its mitochondrial protein replacement (mPRT) platform.

About BioBlast Pharma Ltd.

BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. The Company is rapidly building a diverse portfolio of products candidates with the potential to address unmet medical needs for incurable diseases. The BioBlast platforms are based on deep understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology. BioBlast was founded in 2012 and is traded on the NASDAQ under "ORPN". For more information please visit the Company's website, www.bioblast-pharma.com , the content of which is not incorporated herein by reference.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, we are using forward looking statements when we discuss building a diverse portfolio of products candidates with the potential to address unmet medical needs for incurable diseases, or that our platforms potentially offer solutions for several diseases that share the same biological pathology. Because such statements deal with future events and are based on BioBlast Pharma Ltd.'s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of BioBlast Pharma could differ materially from those described in or implied by the statements in this press release, including those discussed under the heading "Risk Factors" in BioBlast Pharma's registration statement on Form F-1 filed with the Securities and Exchange Commission ("SEC") and in any subsequent filings with the SEC. Except as otherwise required by law, BioBlast Pharma disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

 
BioBlast Pharma Ltd
Statement of Operation
(In thousands, except per share amounts)
 
  Three Months Ended Six Months Ended
  June 30, June 30,
  2014 2013 2014 2013
  (unaudited)  (unaudited)  (unaudited)  (unaudited)
         
Research and development $ 721 $ 48 $ 1,163 $ 66
General and administrative 391 86 590 105
 
Total operating expenses
 
1,112
 
134
 
1,753
 
171
         
Financial expenses, net 2 1 6 2
         
Net comprehensive loss 1,114 135 1,759 173
Net loss attributable to holders of Ordinary shares $ 1,114 $ 135 $ 1,759 $ 173
Net basic and diluted loss per share $ 0.10 $ 0.02 $ 0.16  $ 0.02 
Weighted average number of Ordinary shares used in computing basic and diluted net loss per share 11,030,480 7,551,427 10,873,973 7,551,427

 

 
BioBlast Pharma Ltd.
Balance Sheet Data
(In thousands)
 
ASSETS
 
  June 30,  December 31,
  2014 2013
  (unaudited)  
Current assets:    
Cash and cash equivalents $ 4,243 $ 270
Receivables and prepaid expenses 144 29
 
Total current assets
 
4,387
 
299
 
 
 
   
Long-term assets:    
Long-term deposit 2 5
Property and equipment, net 30 2
Deferred issuance expenses 97 --
 
Total long-term assets
 
129
 
7
     
Total assets $ 4,516 $ 306

 

LIABILITIES AND
SHAREHOLDERS' EQUITY
     
Current liabilities:    
Trade payables $ 277 $ 46
Other accounts payable 438 85
 
Total current liabilities
715 131
     
Shareholders' equity:    
Share capital 30 24
Additional paid-in capital 6,930 1,551
Accumulated deficit (3,159) (1,400)
     
Total shareholders' equity 3,801 175
     
Total liabilities and shareholders' equity $  4,516 $ 306

 

 
BioBlast Pharma Ltd.
Cash Flow Data
(In thousands)
 
  Three Months Ended Six Months Ended
  June 30, June 30,
  2014 2013 2014  2013
  (unaudited) (unaudited) (unaudited) (unaudited)
Cash flow from operating activities:        
Net loss $ (1,114)  $ (135)  $ (1,759)   $ (173) 
Adjustments to reconcile net income to net cash used in operating activities:        
Depreciation 1 -- 1 --
Stock base compensation 5 57 14 60
Change in operating assets and liabilities:        
Receivables and prepaid expenses (78) (6) (115) 3
Long term deposit -- -- 3 --
Trade payables 270 (4) 231 (26)
Other accounts payable 252 4 353 7
 
Net cash used in operating activities
(664) (84)  
(1,272)
 
(129)
         
Cash flow from investing activities:        
         
Purchase of property and equipment (28) -- (29) --
 
Net cash used in investing activities
(28) --  
(29)
--
         
Cash flow from financing activities:        
         
Issuance of shares, net -- -- 5,371 --
Deferred issuance expenses (20) -- (97) --
 
Net cash provided by financing activities
 
(20)
 
--
 
5,274
 
--
         
Increase (decrease) in cash and cash equivalents (712) (84) 3,973 (129)
         
Cash and cash equivalents at the beginning of the period 4,955 101 270 146
         
Cash and cash equivalents at the end of the period $ 4,243 $ 17 $ 4,243 $ 17

U.S. Investor Contact: Michael Rice Founding Partner LifeSci Advisors, LLC (646) 597-6979

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 38

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
Roche Delivers Endotrophin Assay to Nordic Bioscience Lab

Updated Category News Views 52

Roche Opens New Frontier in Diagnostic Biomarkers Get ready to chew on this: Roche Diagnostics is bringing something new to Nordic Bioscience's CLIA lab. They're offering up their Endotrophin research prototype assay on the cobas® e801 Analyzer. Now, what does this mean for the scientific world? Well, it might just shake things up for those battling cardiovascular and...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 71

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 301

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 36

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Bank Hapoalim's Q3 2026: Steady Growth Amid Challenges

Updated Category News Views 105

Digging Deep into Hapoalim's Recent Results Now ain't this a turn of events? Bank Hapoalim rolls out its numbers for Q3 2026, and while there's no confetti dropping from the ceiling, the numbers are telling their own story. Net profit comes to a solid NIS 2,364 million, but we're looking at a landscape that's not all rose-tinted today. The bank's managed to pull off...

Continue Reading
Portillo's Faces Legal Heat: Investor Class Action Filed

Updated Category News Views 23

What’s Eating Portillo's? Ah, once upon a misstep in the land of promising expansion, now we have Portillo's Inc. (NASDAQ: PTLO) neck-deep in legal hot water. Those golden fries and famous sandwiches somehow didn't pave the way for stockholder bliss. Why the turmoil? On an ordinary November morning, the DJS Law Group made it clear: They're rallying the troops for a...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 5

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 92

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading

Top 5 Most Recently Viewed Articles

Banco Comercial Português Adresses Legal Risks of FX Mortgages

Updated Category News Views 191

Understanding Legal Risks in FX Mortgage Loans Banco Comercial Português, S.A. is proactive in addressing estimated legal risks associated with the foreign exchange (FX) mortgage loans portfolio managed by Bank Millennium, S.A. This initiative reflects the bank's commitment to stability and customer security amidst a complex financial landscape. Estimated Provisions for...

Continue Reading
Elevating Dating: MillionaireMatch's New Travel Feature

Updated Category News Views 117

Introducing the New Feature on MillionaireMatch MillionaireMatch, the renowned dating website catering to billionaires and successful individuals, has launched an exciting new feature known as 'Willing to Fly to Meet.' This update empowers users to indicate their readiness to travel distances for a potential romantic connection. By opting into this feature, individuals...

Continue Reading
Whistle Design Sparks Innovation for Coaches and Trainers

Updated Category News Views 151

So, here’s the lowdown: a new whistle design is hitting the scene, aiming to make coaches’ calls clearer amidst the chaos of overlapping games. But let’s not get lost in the novelty—this isn’t just about some fancy gadget; it’s got implications worth dissecting. First up, this invention is supposedly patent-pending. That tag usually raises eyebrows in finance...

Continue Reading
UK Imposes Sanctions on Russian Military for Chemical Warfare

Updated Category News Views 119

UK Sanctions Against Russian Military Forces The UK government has taken a bold step to address the ongoing situation in Ukraine by imposing sanctions on Russian military personnel linked to the use of chemical weapons on the battlefield. This decisive action showcases the UK's commitment to upholding international law and protecting human rights. Targeted Sanctions on...

Continue Reading
PepsiCo Prepares for Challenging Q3 Amid Pricing Pressures

Updated Category News Views 296

PepsiCo's Current Market Position PepsiCo, Inc. (NASDAQ: PEP) continues to show resilience as it navigates a complex economic environment. Recently, the company’s shares have been trading slightly higher, reflecting a degree of investor confidence amidst ongoing market challenges. Analyst Insights on Upcoming Earnings According to analyst Peter T. Galbo from BofA...

Continue Reading